Herma G. Renkema
Nijmegen, GE, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Digital Cognitive Testing in Mitochondrial Disease: Validity and Challenges for Clinical Trial Use.
Journal: Annals of clinical and translational neurology
Published: April 29, 2026
Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation.
Journal: Brain : a journal of neurology
Published: March 06, 2024
The Redox Modulating Sonlicromanol Active Metabolite KH176m and the Antioxidant MPG Protect Against Short-Duration Cardiac Ischemia-Reperfusion Injury.
Journal: Cardiovascular drugs and therapy
Published: April 12, 2021
Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth.
Journal: PloS one
Published: December 19, 2020
Sonlicromanol improves neuronal network dysfunction and transcriptome changes linked to m.3243A>G heteroplasmy in iPSC-derived neurons.
Journal: Stem cell reports
Published: July 30, 2020
Mechanism of action and potential applications of selective inhibition of microsomal prostaglandin E synthase-1-mediated PGE2 biosynthesis by sonlicromanol's metabolite KH176m.
Journal: Scientific reports
Published: July 16, 2020
Live-Imaging Readouts and Cell Models for Phenotypic Profiling of Mitochondrial Function.
Journal: Frontiers in genetics
Published: September 25, 2018
KH176 Safeguards Mitochondrial Diseased Cells from Redox Stress-Induced Cell Death by Interacting with the Thioredoxin System/Peroxiredoxin Enzyme Machinery.
Journal: Scientific reports
Published: January 19, 2018
Corrigendum: NANS-mediated synthesis of sialic acid is required for brain and skeletal development.
Journal: Nature genetics
Published: May 27, 2017
Last Updated: 09/26/2026